Remix to Go Public in Reverse Merger with Once High-Flying Passage Bio

Why It Matters

The transaction gives Remix a public market platform and ample capital while offering Passage shareholders a lifeline, reshaping the competitive landscape for RNA‑based and gene‑therapy innovations.

Key Takeaways

• Remix investors will hold ~93% of post‑merger entity
• $100 million private round secures runway through 2028
• Passage shareholders receive 7% plus contingent value rights
• REM‑422 in Phase 1/2 for AML, MDS, ACC
• Johnson & Johnson and Roche have partnered with Remix

Pulse Analysis

The biotech sector has seen a surge in reverse‑merger listings as companies seek faster access to public capital. Remix Therapeutics, known for its oral RNA‑targeting platform, is leveraging Passage Bio’s public shell to sidestep a traditional IPO. Passage, once a darling with a $700‑per‑share peak, has been battered by market headwinds and regulatory setbacks, leaving its valuation under $4. By merging, Remix gains an immediate ticker—RMTX—while Passage’s remaining shareholders receive a meaningful equity stake and upside tied to future pediatric gene‑therapy milestones.

Financially, the deal is underpinned by a $100 million private financing led by Decheng Capital, slated to close before the merger. Combined cash resources are projected to sustain the new entity’s operations into 2028, a rare multi‑year runway in a capital‑intensive field. Ownership will be heavily skewed toward Remix investors at about 93%, leaving Passage holders with a 7% slice and a contingent right that could unlock additional value if licensed assets succeed. This structure balances risk and reward, offering Passage stakeholders a chance to recoup value while giving Remix the liquidity and credibility of a listed company.

Strategically, the merger aligns two complementary therapeutic approaches: Remix’s pill‑based RNA modulators and Passage’s gene‑therapy pipelines targeting neurodegenerative diseases. Remix’s lead candidate, REM‑422, is already in Phase 1/2 trials for acute myeloid leukemia, high‑risk myelodysplastic syndrome, and adenoid cystic carcinoma, and has attracted partnerships with Johnson & Johnson and Roche. The combined entity can now cross‑leverage these collaborations, accelerate development timelines, and broaden its addressable market. For investors, the transaction signals a growing confidence in RNA‑focused drug platforms and underscores the market’s appetite for hybrid biotech models that blend small‑molecule and gene‑therapy expertise.

Deal Summary

Remix Therapeutics announced it will go public through a reverse merger with gene‑therapy company Passage Bio. The transaction, expected to close in the fourth quarter, will give Remix shareholders about 93% of the combined entity, with Passage shareholders holding 7% and a contingent value right. Remix also secured a $100 million private financing round that will close before the merger.